军事知识服务平台
活体共聚焦显微镜对睑板腺功能障碍患者睑板腺形态检测的应用研究
In vivo confocal microscopy evaluation of meibomian glands in meibomian gland dysfunction patients
摘要 目的:探讨活体共聚焦显微镜(IVCM)下的睑板腺功能障碍(MGD)患者睑板腺腺泡形态、周围组织纤维化及炎性反应浸润的表现及意义。方法前瞻性病例对照研究。选取2015年8月至2016年1月在北京同仁医院眼科中心就诊的20例MGD患者(20只眼)及15例对照组(15只眼)。对受试者分别进行眼表疾病评分指数(OSDI)问卷调查、睑缘及眼表裂隙灯显微镜检查、泪膜破裂时间测定(TBUT)、角结膜荧光素染色、泪液分泌试验(SchirmerⅠ)检测、红外线睑板腺照相及IVCM检查。睑板腺IVCM观察指标包括睑板腺腺泡最长径、腺泡最短径(MGASD)、腺泡单元密度、腺泡单元面积、睑板腺周围炎症细胞密度及腺体纤维化程度。MGD组及对照组的各项计量指标比较,正态分布数据采用独立样本t检验,非正态分布数据采用秩和验检;两组受检者相关参数严重程度比较采用卡方检验进行比较分析。结果 MGD组患者OSDI评分为(31.80±22.97)分,高于对照组(7.93±6.51)分(t=-3.92,P=0.001);MGD患者睑缘评分为(3.10±0.31)分、睑板腺平均缺失率为(38.31±19.94)%、角结膜染色评分1.00(2.75)分,均明显高于对照组的(0.33±0.31)分、(21.31±7.70)%及0.00(1.00)分,差异均有统计学意义(t=20.54,3.12;U=-2.22;P<0.05);MGD组TBUT为(3.35±2.28)s,较对照组(6.67±2.51)s明显减小(t=-4.09,P<0.001),而SchirmerⅠ检测两组差异无统计学意义(t=-1.52,P=0.139)。MGD组患者睑板腺腺泡最长径为(156.80±46.10)μm、腺泡最短径为(38.75±11.72)μm、腺泡单元面积(10113.84±5531.21)μm 2、炎症细胞密度(621.90±405.63)个/mm2明显大于对照组的(67.47±9.12)μm、(22.00±2.95)μm、(3102.13±1111.97)μm 2、(188.80±72.25)个/mm2,差异均有统计学意义(t=7.37,5.39,4.82,4.07;P均<0.001);MGD组睑板腺腺泡单元密度为(61.10±34.97)个/mm2,较对照组(105.07±18.58)个/mm2明显降低,差异有统计学意义(t=-4.41,P<0.001);纤维化程度为1.50(1.00)级,高于对照组0.00(0.00)级,差异有统计学意义(U=-4.03,P=0.001)。结论 IVCM显示MGD患者睑板腺开口形状不规则、睑板腺腺泡囊样扩张或萎缩、腺泡间炎症细胞浸润及纤维化改变,对MGD的诊断具有潜在的应用价值。(中华眼科杂志,2016,52:649-656)
Abstract:
Objective To observe the morphology, fibrosis grade and inflammatory infiltration of meibomian glands using in vivo confocal microscopy (IVCM) in meibomian gland dysfunction (MGD) patients. Methods A prospective case-controlled study. According to the diagnostic criteria of MGD, 20 MGD patients (20 eyes) were included in our study from August to October 2015. Fifteen normal subjects (15 eyes)were also studied. Methods All subjects completed the questionnaire of the Ocular Surface Disease Index (OSDI), lid margin and ocular surface examination by slit lamp microscropy, tear film break-up time (TBUT) test, corneal and conjunctival staining (Oxford scale), Schirmer I test, infrared meibomian photography and IVCM. Main outcomes in IVCM included meibomian gland acinar longest diameter (MGALD), meibomian gland acinar shortest diameter (MGASD), meibomian gland acinar unit density (MGAUD), meibomian gland acinar unit area (MGAUA), meibomian gland inflammatory cell density and fibrosis degree. The parameters between the MGD group and the control group were compared using the independent samples t test.Results The OSDI score[(31.80±22.97) points], 1id margin abnormality score [(3.10±0.31) points], loss rate of meibomian glands(38.31%±19.94%)and corneal and conjunctival staining score [1.00(2.75) points]in the MGD group were obviously higher than those in the control group [(7.93±6.51) points, (0.33 ± 0.31) points, 21.31%± 7.70%, and 0.00(1.00) points, P=0.001, P<0.001, P=0.004, and P=0.037, respectively]. The TBUT was significantly lower in the MGD group [(3.35±2.28)s] than in the control group [(6.67 ± 2.51)s, P<0.001]. According to Schirmer I test, there was no significant difference in the two groups (P=0.139). The mean values of MGALD[(156.80 ± 46.10)μm], MGASD[(38.75 ± 11.72)μm], MGAUA [(10 113.84 ± 5 531.21)μm2], meibomian gland inflammatory cell density[(621.90 ± 405.63) cells/mm2]and fibrosis degree 1.50(1.00) in the MGD patients were larger than those in the control group [(67.47 ± 9.117)μm, (22.00 ± 2.95)μm, (3 102.13 ± 1111.97)μm2, (188.80 ± 72.25) cells/mm2, and 0.00(0.00), all P<0.001, respectively]. The mean MGAUD was lower in the MGD patients[(61.10 ± 34.97) glands/mm2]than in the control group [(105.07±18.58) glands/mm2, P<0.001]. Conclusions IVCM was pertinent to investigate the meibomian glands by detecting the irregularity of meibomian orifices, the diameter and area, and the inflammation and fibrosis levels in MGD patients. It may have a potential clinical value for the diagnosis of MGD.
Author: Liang Qingfeng Gao Chao Liang Hong Du Xianghong Wang Ningli Labbe Antoine
作者单位: 100005首都医科大学附属北京同仁医院北京同仁眼科中心北京市眼科研究所北京市眼科学与视觉科学重点实验室 法国Quinze Vingts国立眼科医院
刊 名 中华眼科杂志 ISTICPKU
年,卷(期): 2016, 52(9)
机标分类号: R777.340.5 R591.412 TH744.41
在线出版日期: 2016年9月27日
基金项目: 2014-3-016:北京市卫生系统高层次卫生技术人才培养计划工程)学科骨干项目W2013BJ47:科研发展项目,